MedTrace Logo

Women at Risk of Breast Cancer and OLFM4

NCT02653105 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-08-15

No results posted yet for this study

Summary

Does the olfactomédine provide an help to limit the number of false positives in the overall imaging balance and limit the number of unnecessary biopsies?

Conditions

  • Hereditary Breast and Ovarian Cancer Syndrome

Interventions

BIOLOGICAL

OLFM4

patient have an additional blood test every 6 months for dosing OLFM4

Sponsors & Collaborators

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • Paule AUGEREAU, MD · Institut de Cancérologie de l'Ouest - ANGERS

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-08
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02653105 on ClinicalTrials.gov